What is Corium?
Corium, LLC operates as a specialized biopharmaceutical entity dedicated to the development and commercialization of innovative neuroscience therapies. By bridging the gap between complex clinical research and patient-centric care, the company has successfully brought two FDA-approved products, ADLARITY and AZSTARYS, to the U.S. market. Beyond its domestic footprint, Corium has adopted a strategic licensing model to facilitate the development and commercialization of these assets in international territories. This dual-pronged approach of internal innovation and global partnership positions the company as a significant player in the neurology sector, focusing on high-unmet-need conditions that require sophisticated delivery mechanisms and clinical precision.
How much funding has Corium raised?
Corium has raised a total of $556M across 2 funding rounds:
Stock Offering
$52M
Private Equity
$504M
Stock Issuance/Offering (2014): $52M, investors not publicly disclosed
Private Equity (2018): $504M led by Gurnet Point Capital
Key Investors in Corium
Gurnet Point Capital
Gurnet Point Capital is a healthcare-focused investment firm that employs a hybrid strategy of venture and private equity to support life sciences and medical technology companies through all stages of development.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Corium?
With the recent influx of capital, Corium is well-positioned to accelerate its commercialization efforts and potentially broaden its therapeutic pipeline. The company's strategic roadmap likely involves deepening its market penetration for ADLARITY and AZSTARYS while exploring new indications or delivery technologies that leverage its existing expertise. As the firm matures, the focus will likely shift toward optimizing supply chain efficiencies and navigating the regulatory complexities of international expansion. By maintaining a disciplined approach to capital allocation, Corium aims to sustain its momentum in the neuroscience space, ensuring that its innovative treatment options remain accessible to the patient populations that rely on them most.
See full Corium company page
